#1
#1 out of 1100.00%
business3h ago
Key facts: GSK Q2 & HIV patent‑cliff; tests Summit PD‑1/VEGF + B7H3 ADC
- GSK plans a portfolio event to discuss Q2 results and HIV patent-cliff strategy.
- Summit will test its PD-1/VEGF bispecific with GSK’s B7-H3 ADC across solid tumors.
- The collaboration targets small cell lung cancer among other solid tumors.
- TradingView notes potential exclusivity losses tied to HIV patent issues.
- GSK expects Phase III trials to begin as part of its strategy.
- Mergers and acquisitions activity around GSK could offset losses.
- The news center on GSK’s strategy amid HIV patent cliff pressures.
- The collaboration includes ivonescimab with risvutatug rezetecan across solid tumors.
- The report emphasizes ongoing trials and collaboration as core to the plan.
- The coverage originates from TradingView News and summarizes key facts.
Vote 0